<SEC-DOCUMENT>0001104659-19-074693-index.html : 20191220
<SEC-HEADER>0001104659-19-074693.hdr.sgml : 20191220
<ACCEPTANCE-DATETIME>20191220090705
ACCESSION NUMBER:		0001104659-19-074693
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20191220
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20191220
DATE AS OF CHANGE:		20191220

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nabriva Therapeutics plc
		CENTRAL INDEX KEY:			0001641640
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L2
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37558
		FILM NUMBER:		191297804

	BUSINESS ADDRESS:	
		STREET 1:		56 FITZWILLIAM SQUARE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			2
		BUSINESS PHONE:		(610) 816-6640

	MAIL ADDRESS:	
		STREET 1:		1000 CONTINENTAL DRIVE
		STREET 2:		SUITE 600
		CITY:			KING OF PRUSSIA
		STATE:			PA
		ZIP:			19406

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Nabriva Therapeutics AG
		DATE OF NAME CHANGE:	20150507
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm1926567-4_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
Document 1 - file: tm1926567-4_8k.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>tm1926567d4_ex4-1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
Document 2 - file: tm1926567d4_ex4-1.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>tm1926567d4_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
Document 3 - file: tm1926567d4_ex10-1.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>tm1926567d4_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
Document 4 - file: tm1926567d4_ex99-1.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>tm1926567d4_ex99-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 5 - file: tm1926567d4_ex99-1img01.jpg

</DOCUMENT>
</SEC-DOCUMENT>